136 related articles for article (PubMed ID: 8053886)
1. EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia.
Quinn M; Murray J; Friedlander M; Steigrad S; Khoo S; Marsden D; Hammond I; Jobling T
Aust N Z J Obstet Gynaecol; 1994 Feb; 34(1):90-2. PubMed ID: 8053886
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
[TBL] [Abstract][Full Text] [Related]
3. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
[TBL] [Abstract][Full Text] [Related]
4. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
[TBL] [Abstract][Full Text] [Related]
5. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
Surwit EA; Childers JM
J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
[TBL] [Abstract][Full Text] [Related]
6. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
8. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
Kohorn EI
Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
[TBL] [Abstract][Full Text] [Related]
9. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984).
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Holden L; Dent J
Br J Obstet Gynaecol; 1986 Jan; 93(1):63-9. PubMed ID: 3002420
[TBL] [Abstract][Full Text] [Related]
10. Gestational trophoblastic disease.
Hammond CB; Olt GJ
Curr Ther Endocrinol Metab; 1994; 5():567-70. PubMed ID: 7704794
[No Abstract] [Full Text] [Related]
11. [Treatment of patients with trophoblastic tumors in the Academic Medical Center: 31 patients in 10 years, 1983-1992].
Laan R; Bakker P; Lammes FB
Ned Tijdschr Geneeskd; 1995 Sep; 139(36):1829-34. PubMed ID: 7477506
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors.
Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S
Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405
[TBL] [Abstract][Full Text] [Related]
13. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
Bower M; Newlands ES; Holden L; Short D; Brock C; Rustin GJ; Begent RH; Bagshawe KD
J Clin Oncol; 1997 Jul; 15(7):2636-43. PubMed ID: 9215835
[TBL] [Abstract][Full Text] [Related]
14. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD.
Kim SJ; Bae SN; Kim JH; Kim CT; Han KT; Lee JM; Jung JK
Int J Gynaecol Obstet; 1998 Apr; 60 Suppl 1():S85-96. PubMed ID: 9833620
[TBL] [Abstract][Full Text] [Related]
15. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
[TBL] [Abstract][Full Text] [Related]
16. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
Cyriac S; Rajendranath R; Sridevi V; Sagar TG
J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of central co-ordinated EMA/CO for gestational trophoblastic disease in the Netherlands.
van der Houwen C; Rietbroek RC; Lok CA; Ten Kate-Booij MJ; Lammes FB; Ansink AC
BJOG; 2004 Feb; 111(2):143-7. PubMed ID: 14723751
[TBL] [Abstract][Full Text] [Related]
18. [Etoposide (VP-16) in gynecologic malignancy].
Kanazawa K; Moromizato H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799
[TBL] [Abstract][Full Text] [Related]
19. Treatment of gestational trophoblastic tumors.
Lurain JR
Curr Treat Options Oncol; 2002 Apr; 3(2):113-24. PubMed ID: 12057074
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary hypertension--a rare presentation of choriocarcinoma.
Gangadharan VP; Chitrathara K; Sivaramakrishnan R; Satishkumar K; Nair MK
Acta Oncol; 1993; 32(4):461-2. PubMed ID: 8396399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
